ProCE Banner Activity

Phase II SOLTI VALENTINE: Neoadjuvant HER3-DXd ± Letrozole for High-Risk HR+/HER2- EBC

Conference Coverage
Slideset

The phase II SOLTI VALENTINE trial of neoadjuvant HER3-DXd with or without letrozole showed comparable pathologic complete response and overall response rates with fewer adverse events than seen with multiagent chemotherapy in previously untreated patients with high-risk HR+/HER2- EBC.

Released: December 16, 2024

Expiration: June 15, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Lilly, Merck Sharp & Dohme LLC, and Novartis Pharmaceuticals Corporation.

Lilly

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation